Evidence map›Paper›PMID 30861422›Full record

ArticleBiomaterials2019

A tetrameric protein scaffold as a nano-carrier of antitumor peptides for cancer therapy.

Bohan Ma, Fan Niu, Xiaoyan Qu, Wangxiao He, Chao Feng, Simeng Wang, Zhenlin Ouyang, Jin Yan, Yurong Wen, Dan Xu and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Nanomedicines Targeting Metabolism in the Tumor Microenvironment.Frontiers in bioengineering and biotechnology · 2022
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Bohan MaCenter for Translational Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China; Institute of Human Virology and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Fan NiuCenter for Translational Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China; Institute of Human Virology and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Xiaoyan QuCenter for Translational Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.
Wangxiao HeCenter for Translational Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China; Institute of Human Virology and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Chao FengCenter for Translational Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.
Simeng WangCenter for Translational Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.
Zhenlin OuyangCenter for Translational Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.
Jin YanCenter for Bioengineering and Regenerative Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China; Department of Biologic and Materials Sciences, Department of Biomedical Engineering, Macromolecular Science and Engineering Center, Department of Materials Science and Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
Yurong WenCenter for Translational Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.
Dan XuCenter for Translational Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China; Institute of Human Virology and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Yongping ShaoCenter for Translational Medicine, Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.
Peter X MaDepartment of Biologic and Materials Sciences, Department of Biomedical Engineering, Macromolecular Science and Engineering Center, Department of Materials Science and Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
Wuyuan LuInstitute of Human Virology and Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. Electronic address: wlu@ihv.umaryland.edu.
Xi'an Jiaotong University · CNUniversity of Maryland, Baltimore · USUniversity of Michigan–Ann Arbor · US

Funding

Anticancer peptide therapeuticsR01CA219150 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, YIN · 2017 to 2022
$1.7M
D-peptide activators of p53 as anticancer therapeuticsR21CA167296 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI LU, WUYUAN · 2014 to 2015
$367k
NCI NIH HHS R01 CA219150NCI NIH HHS R21 CA167296
6 · The paper itself

Abstract

A major pharmacological barrier to peptide therapeutics is their susceptibility to proteolytic degradation and poor membrane permeability, which, in principle, can be overcome by nanoparticle-based delivery technologies. Proteins, by definition, are nano materials and have been clinically proven as an efficient delivery vehicle for small molecule drugs. Here we describe the design of a protein-based peptide drug carrier derived from the tetramerization domain of the chimeric oncogenic protein Bcr/Abl of chronic myeloid leukemia. A dodecameric peptide inhibitor of the p53-MDM2/MDMX interaction, termed PMI, was grafted to the N-terminal helical region of Bcr/Abl tetramer. To antagonize intracellular MDM2/MDMX for p53 activation, we extended this protein,

Indexed as

Protein MultimerizationAmino Acid SequenceAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell Membrane PermeabilityCell ProliferationDrug CarriersHumansKineticsMice, NudeNanoparticlesNeoplasmsPeptidesProteolysisAntineoplastic AgentsDrug CarriersPeptidesTumor Suppressor Protein p53Anticancer peptidesBcr/AblMDM2p53Peptide drug deliveryProtein therapeutics

Identifiers

PMID30861422
PMCPMC6441627
OpenAlexW2921089053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.